نتائج البحث

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.

• Authors : Strober, Bruce¹ ; Duffin, Kristina Callis²; Lebwohl, Mark³

• Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-8. 8p.

تفاصيل العنوان

Multiarm study comparing patient-reported and clinical outcome measures in patients undergoing antipsoriatic therapy with non-biological systemic agents in a real-world setting.

• Authors : Fink, Christine¹ (AUTHOR) ; Alt, Christina² (AUTHOR); Schank, Timo E.¹ (AUTHOR)

• Source: Journal of Dermatological Treatment. Nov2022, Vol. 33 Issue 7, p2997-3004. 8p.

تفاصيل العنوان

Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.

• Authors : Strober, Bruce^1,2 (AUTHOR) ; Patil, Dhaval³ (AUTHOR); McLean, Robert R.⁴ (AUTHOR)

• Source: Journal of Dermatological Treatment. Dec2022, Vol. 33 Issue 8, p3178-3187. 10p.

تفاصيل العنوان

Disease response and patient-reported outcomes among initiators of ixekizumab.

• Authors : Shahriari, Mona^1,2 (AUTHOR); Harrison, Ryan W.³ (AUTHOR); Burge, Russel^4,5 (AUTHOR)

• Source: Journal of Dermatological Treatment. May2022, Vol. 33 Issue 3, p1538-1546. 9p.

تفاصيل العنوان

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.

• Authors : Magnolo N; Department of Dermatology and Venereology, University Hospital of Münster, Münster, Germany.; Cameron MC

Subjects: Quality of Life* ; Dermatitis, Atopic*/Dermatitis, Atopic*/Dermatitis, Atopic*/drug therapy ; Pruritus*/Pruritus*/Pruritus*/drug therapy

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2344589. Date of Electronic Publication: 2024 May 02.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.

• Authors : Hebert AA; UTHealth McGovern Medical School, Houston, Texas, USA.; Flohr C

Subjects: Dermatitis, Atopic*/Dermatitis, Atopic*/Dermatitis, Atopic*/drug therapy ; Severity of Illness Index*; Humans

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2324833. Date of Electronic Publication: 2024 May 12.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

• Authors : Nina Magnolo; Michael C. Cameron; Mona Shahriari

Subjects: Atopic dermatitis; disease burden; patient-reported outcome measures

• Source: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

تفاصيل العنوان

Patient reported outcomes for intensified versus conventional NB-UVB treatment in non-segmental vitiligo.

• Authors : Uitentuis SE; a Netherlands Institute for Pigment Disorders, Department of Dermatology, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam , the Netherlands.; Narayan VS

Subjects: Patient Reported Outcome Measures*; Ultraviolet Therapy/Ultraviolet Therapy/Ultraviolet Therapy/*methods ; Vitiligo/Vitiligo/Vitiligo/*therapy

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2019 Sep; Vol. 30 (6), pp. 594-597. Date of Electronic Publication: 2018 Nov 29.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.

• Authors : Armstrong A; a Keck School of Medicine , University of Southern California , Los Angeles , CA , USA.; Puig L

Subjects: Patient Reported Outcome Measures*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Dermatologic Agents/Dermatologic Agents/Dermatologic Agents/*therapeutic use

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2019 Feb; Vol. 30 (1), pp. 27-34. Date of Electronic Publication: 2018 Sep 24.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.

• Authors : Thyssen JP; Department of Dermatology and Venersology, Bispebjerg Hospital, Copenhagen, Denmark.; Werfel T

Subjects: Dermatitis, Atopic*/Dermatitis, Atopic*/Dermatitis, Atopic*/drug therapy; Adult ; Humans

• Source: The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2190430.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print Cited Medium: Internet ISSN: 1471-1753

تفاصيل العنوان